Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31522121 | 0.89 | HCAR2 (0.70) | KMT2AMEN1HCAR2ALDH1A1L3MBTL1 | |
| SCHEMBL229650 | 0.78 | KMT2A (1.00) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| SCHEMBL185925 | 0.78 | — | — | |
| SCHEMBL30706508 | 0.77 | ALDH1A1 (0.69) | KMT2AMEN1HCAR2ALDH1A1ATM | |
| SCHEMBL125431 | 0.77 | ALDH1A1 (0.69) | KMT2AMEN1HCAR2ALDH1A1ATM | |
| Pyridazine SCHEMBL19535239 | 0.77 | HCAR2 (0.87) | HCAR2ALDH1A1TBXA2RTBXAS1MAPT | |
| Benzophenone SCHEMBL27778625 | 0.77 | ALDH1A1 (0.88) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Benzophenone SCHEMBL28035103 | 0.77 | ALDH1A1 (0.88) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Benzophenone SCHEMBL6339732 | 0.77 | ALDH1A1 (0.88) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Benzophenone SCHEMBL6061130 | 0.76 | ALDH1A1 (1.00) | KMT2AMEN1ALDH1A1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| US-8466151-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-8466151-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20110152281-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20110152281-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20110152281-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2225226-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | Critical Outcome Technologies, Inc. (CA) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009079797-A9 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079797-A9 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079797-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009079797-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | KMT2A 1410/4885MEN1 4539/4885HCAR2 108/4885 |
| US-20110152281-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | SLCO1B3, SLCO2B1, SLCO1B1 | KMT2A 2933/4885MEN1 1473/4885HCAR2 1514/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | KMT2A 854/4885MEN1 2976/4885HCAR2 60/4885 |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | P2RX5, P2RX7, P2RX6 | KMT2A 854/4885MEN1 2976/4885HCAR2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.